Search for: "ASTRAZENECA LP" Results 1 - 20 of 161
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
4 Jan 2022, 6:00 am by Douglas J. Bucklin, Ph.D.
Cir. 2021) 2021-1729 AstraZeneca AB and AstracZeneca Pharmacueticals LP (AstraZeneca) sued Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. [read post]
9 Dec 2021, 7:15 am by Logan Murr
The decision relates to AstraZeneca AB’s and AstraZeneca Pharmaceuticals LP’s (collectively “AstraZeneca”) lawsuit against Mylan and Kindeva Drug Delivery LP (collectively “Mylan”) for infringing all claims of U.S. [read post]
8 Dec 2021, 8:52 am by Lawrence B. Ebert
The outcome AstraZeneca AB and AstraZeneca Pharmaceuticals LP (collectively, “AstraZeneca”) sued Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. [read post]
5 Aug 2021, 12:12 pm by Lawrence B. Ebert
The outcome was a vacating of the district court's grant of JMOL and a lot of discussion of drug "skinny labels": GlaxoSmithKline LLC and SmithKline Beecham (Cork) Ltd. [read post]
12 Feb 2018, 12:05 pm by Tom Lamb
According to that JPML Transfer Order the Defendants -- AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co., and McKesson Corp. -- opposed centralization of approximately 80 Onglyza and Kombiglyze lawsuits into this new MDL: Defendants oppose transfer by arguing that plaintiffs’ allegations are supported by a single study (the SAVOR study), which itself supports only claims regarding heart failure – not the various other injuries (congestive heart failure, acute… [read post]
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
12 May 2017, 9:05 am by Tom Lamb
., AstraZeneca Pharmaceuticals LP, AstraZeneca LP, AstraZeneca PLC, and AstraZeneca AB (collectively, Bristol-Myers/AstraZeneca), which developed, manufactured, and marketed the drugs, failed to adequately test the drugs and warn of their risks. [read post]
28 Feb 2017, 7:39 am by Dennis Crouch
 The particular claims require “a continuous long term regimen . . . at a dosage up to 1.5 mg/kg/day for not less than 45 days” for treating “an individual with … penile tunical fibrosis …” On anticipation, the court drew a fine-line with its closest case being AstraZeneca LP v. [read post]
8 Dec 2016, 2:00 am by Linda O'Brien
Linda O'BrienCCHPurchasers of AstraZeneca LP’s heartburn medication Nexium were not entitled to a new trial to their challenge of “reverse payment” agreements between AstraZeneca and Ranbaxy Pharmaceuticals that allegedly blocked the entry of a generic version of the drug, the U.S. [read post]
29 Aug 2016, 12:30 pm by Tom Lamb
For use as an example, here is the relevant part of an August 17, 2016 FDA Supplemental Approval letter to AstraZeneca Pharmaceuticals LP for Farxiga: Please refer to your supplemental New Drug Application (sNDA) dated and received July 28 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Farxiga (dapagliflozin) tablets. [read post]
15 Apr 2016, 8:26 am by Tom Lamb
These medications are available by prescription and over-the-counter (OTC) from various pharmaceutical companies, for example: PRILOSEC (omeprazole magnesium) | prescription drug | AstraZeneca LPPRILOSEC OTC (omeprazole magnesium) | over-the-counter | Procter & Gamble Manufacturing Co.PREVACID (lansoprazole) | prescription drug | Takeda Pharmaceuticals America, Inc.PREVACID 24 HR (lansoprazole) | over-the-counter | Novartis Consumer Health, Inc.NEXIUM (esomeprazole magnesium) |… [read post]